• **Name:** Hyung-Don Kim

• **Current Position & Affiliation:** Assistant professor & University of Ulsan, Asan Medical Center

• **Country:** Republic of Korea

• Educational Background:

- B.S. Chung-Ang University College of Medicine, Seoul, Korea, 2005-2011
- M.S. University of Ulsan College of Medicine, Seoul, Korea, 2014-2016
- Ph.D. Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea, 2016-2020

• Professional Experience:

- Intern, Asan Medical Center, Seoul, Korea, 2011-2012
- Resident, Department of Internal Medicine, Asan Medical Center, Seoul, Korea, 2012-2016
- Clinical fellow, Department of Oncology, Asan Medical Center, Seoul, Korea, 2020-2021
- Clinical Instructor, Department of Oncology, Asan Medical Center, Seoul, Korea, 2021-2022
- Assistant Professor, Department of Oncology, Asan Medical Center, Seoul, Korea, 2021-2022

• Professional Organizations:

- American Society of Clinical Oncology
- European Society of Medical Oncology
- The Korean Association of Immunologists
- Korean Cancer Association
- Korean Society of Medical Oncology
- Korean Cancer Study Group
- The Korean Liver Cancer Study Group

• Main Scientific Publications in the Field of Translational Research:

- Association Between Expression Level of PD1 by Tumor-Infiltrating $CD8^+$ T Cells and Features of Hepatocellular Carcinoma. **Gastroenterology.** 2018 Dec;155(6):1936-1950.
- 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T cells in Hepatocellular Carcinoma. **Hepatology** 2018 Dec;155(6):1936-1950.
- Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade **J Immunother Cancer.** 2021 Jul;9(7):e002428.
- Insertion-Deletion Rate is a Qualitative Aspect of the Tumor Mutation Burden Associated with the Clinical Outcomes of Gastric Cancer Patients Treated with Nivolumab. **Gastric Cancer.** 2022 Jan;25(1):226-234.
- Implication of CD69+CD103+ Tissue-resident-like CD8+ T cells as a Potential Immunotherapeutic Target for Cholangiocarcinoma **Liver Int.** 2021 Apr;41(4):764-776.
- Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer. **Cancer Res Treat.** 2021 Jan;53(1):162-171.